The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
|Videos|August 29, 2017
Role of Surgery in Mesothelioma
Author(s)Joseph S. Friedberg, MD
This video reviews the role of surgery in the management of patients with mesothelioma.
Advertisement
In this video, Joseph S. Friedberg, MD, of the University of Maryland School of Medicine in Baltimore, discusses the role of surgery in patients with mesothelioma and highlights a
Friedberg gave a presentation on this topic earlier this year at the 2017 Multidisciplinary Thoracic Cancers Symposium.
Advertisement
Related to this article
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Daniel C. McFarland, DO, and Ramy Sedhom, MD, discussed co-located psycho-oncology and palliative care, warm handoffs, and proactive distress screening.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care
3
Targeting Cyclin E1, KRAS, and DNA Repair Beyond PARP in Ovarian Cancer
4
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
5